Anti-SLAMF7 Polyclonal Antibody for WB and ELISA - Q9NQ25

Core Product Specifications and Parameters

Biological Background: SLAMF7 Function and Localization

• SLAMF7 (also known as CS1, CD319, CRACC) is a transmembrane receptor of the signaling lymphocytic activation molecule (SLAM) family, with two main isoforms produced by alternative splicing; isoform 1 mediates immune cell activation, while isoform 3 lacks activating function.
• Isoform 1 triggers NK cell activation through an SH2D1A-independent ERK-mediated pathway and positively regulates NK cell functions via phosphorylated SH2D1B, involving downstream signaling through PLCG1, PLCG2, and PI3K. Related references: PMID:11698418, PMID:16339536
• In the absence of SH2D1B, SLAMF7 can inhibit NK cell function; it also plays an inhibitory role in T-cells. Additionally, in LPS-activated monocytes, it negatively regulates the production of pro-inflammatory cytokines. Related references: PMID:23695528
• SLAMF7 may contribute to lymphocyte adhesion. Related references: PMID:11802771
• It is a membrane glycoprotein containing an immunoglobulin domain, and is classified under both innate and adaptive immunity keywords.
• SLAMF7 is predominantly expressed in immune-related tissues including spleen, lymph node, peripheral blood leukocytes, and bone marrow, with high levels in NK cells, activated B-cells, and monocytes. Isoform 3 is expressed at much lower levels.
• As a glycosylated protein, its observed molecular weight may differ from the predicted 37 kDa.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 23–226 of human SLAMF7 (extracellular domain), which may enable detection of both membrane-bound and soluble receptor forms.
• Due to glycosylation, the apparent molecular weight in Western blot may exceed the predicted 37 kDa; validate the band size using appropriate controls.
• This polyclonal antibody is suitable for WB and ELISA; optimize dilution, blocking, and incubation conditions for your specific sample type.
• Cross-reactivity with human, mouse, and rat SLAMF7 allows use in common experimental models; confirm specificity by testing in relevant tissues or cell lines.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves diagnostic manufacturers and research laboratories with a comprehensive portfolio of IVD raw materials, including validated antibody pairs, optimized polyclonal and monoclonal antibodies, and bulk ancillary reagents. This anti-SLAMF7 antibody supports investigations into innate and adaptive immunity, with particular relevance to NK cell biology and cancer immunotherapy. Our one-stop sourcing platform also facilitates procurement of rare-target materials, helping you streamline development from concept to clinical application.